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Discussion
Dr Frank W. Sellke (Boston, Mass). You showed pretty
clearly that you see increased activation of the caspases. Did you
look at something such as TUNEL assay to be sure that you are
actually seeing apoptosis rather than some inflammatory effect of
gene transfer or some other mechanism causing the cell death?
Dr Kim. There are a lot of assays for apoptosis, and actually in
our laboratory the results of TUNEL assay have been pretty
variable. Even though we can see apoptosis by structure and
activation or cleavage of caspases, we actually find with the
caspase stain that I showed that we have a better assessment that
caspases were indeed activated. Nevertheless, in these cell lines I
have not done any assessment of DNA fragmentation by DNA
laddering, TUNEL assay, or PARP cleavage.
Dr G. Alexander Patterson (St Louis, Mo). You acknowledge
some of the limitations of the study. There may be another limi-
tation. Is it correct that you studied two cell lines?
Dr Kim. Yes.
Dr Patterson. Do you have any comment about that and why
those particular cell lines were selected, or do you have any
preliminary data from other cell lines? In addition, I didn’t under-
stand exactly what the adenoviral control was and why you se-
lected that control versus some other control.
Dr Kim. I will answer the second question first. We have used
several controls. One would be an adenovirus that has no inserted
gene, and the control I showed was an adenovirus that overex-
presses the green fluorescent protein (Ad-EGFP). That is for two
reasons. When we look under a fluorescent microscope we see at
that dose (MOI 50) the adenovirus that overexpresses green fluo-
rescent protein. We can show that infectivity occurred in more than
90% of the cells. In terms of nonspecific cell death induced by
overexpressing any nonspecific protein, Ad-EGFP was the control
that we used. An empty adenovirus (Ad-control) is just a control
for nonspecific adenoviral toxicity.
As for the first question, we have actually done some prelim-
inary studies in other cell lines. We have looked at a couple of
adenocarcinoma cell lines, and we don’t see as much cell death as
we do in the squamous carcinoma cell lines; however, when you
look at the green fluorescent protein expression in adenocarcinoma
cells, there is less infectivity of those cells as well. So we are not
sure if the adenovirus is not getting into the cells to express the
FADD protein as an explanation for why we don’t see as much cell
death. So there is some variability between cell lines in terms of
the induction of cell death. I chose to present the NCI-H226 cell
line particularly because it made a pretty good movie in terms of
demonstrating apoptotic cell death.
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